Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Role of phospholipase D in bleomycin-induced mitochondrial reactive oxygen species generation, mitochondrial DNA damage and pulmonary fibrosis.

Suryadevara V, Huang L, Kim SJ, Cheresh S, Shaaya M, Bandela M, Fu P, Feghali-Bostwick CA, Di Paolo G, Kamp DW, Natarajan V.

Am J Physiol Lung Cell Mol Physiol. 2019 May 15. doi: 10.1152/ajplung.00320.2018. [Epub ahead of print]

PMID:
31090437
2.

Long intergenic non-coding RNAs regulate human lung fibroblast function: Implications for idiopathic pulmonary fibrosis.

Hadjicharalambous MR, Roux BT, Csomor E, Feghali-Bostwick CA, Murray LA, Clarke DL, Lindsay MA.

Sci Rep. 2019 Apr 15;9(1):6020. doi: 10.1038/s41598-019-42292-w.

3.

Integrative analysis of DNA methylation in discordant twins unveils distinct architectures of systemic sclerosis subsets.

Ramos PS, Zimmerman KD, Haddad S, Langefeld CD, Medsger TA Jr, Feghali-Bostwick CA.

Clin Epigenetics. 2019 Apr 4;11(1):58. doi: 10.1186/s13148-019-0652-y.

4.

NADPH oxidase-mediated induction of reactive oxygen species and extracellular matrix deposition by insulin-like growth factor binding protein-5.

Yasuoka H, Garrett SM, Nguyen XX, Artlett CM, Feghali-Bostwick CA.

Am J Physiol Lung Cell Mol Physiol. 2019 Apr 1;316(4):L644-L655. doi: 10.1152/ajplung.00106.2018. Epub 2019 Feb 27.

PMID:
30810066
5.

Long Non-coding RNAs Are Central Regulators of the IL-1β-Induced Inflammatory Response in Normal and Idiopathic Pulmonary Lung Fibroblasts.

Hadjicharalambous MR, Roux BT, Feghali-Bostwick CA, Murray LA, Clarke DL, Lindsay MA.

Front Immunol. 2018 Dec 11;9:2906. doi: 10.3389/fimmu.2018.02906. eCollection 2018.

6.

Intracellular Heat Shock Protein 70 Deficiency in Pulmonary Fibrosis.

Sellares J, Veraldi KL, Thiel KJ, Cárdenes N, Alvarez D, Schneider F, Pilewski JM, Rojas M, Feghali-Bostwick CA.

Am J Respir Cell Mol Biol. 2019 Jun;60(6):629-636. doi: 10.1165/rcmb.2017-0268OC.

PMID:
30543447
7.

Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2.

Schniering J, Benešová M, Brunner M, Haller S, Cohrs S, Frauenfelder T, Vrugt B, Feghali-Bostwick CA, Schibli R, Distler O, Mueller C, Maurer B.

Ann Rheum Dis. 2019 Feb;78(2):218-227. doi: 10.1136/annrheumdis-2018-214322. Epub 2018 Nov 17. Erratum in: Ann Rheum Dis. 2019 Jun;78(6):e60.

8.

Pro-fibrotic phenotype of human skin fibroblasts induced by periostin via modulating TGF-β signaling.

Kanaoka M, Yamaguchi Y, Komitsu N, Feghali-Bostwick CA, Ogawa M, Arima K, Izuhara K, Aihara M.

J Dermatol Sci. 2018 May;90(2):199-208. doi: 10.1016/j.jdermsci.2018.02.001. Epub 2018 Feb 6.

PMID:
29433908
9.

Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis.

Artlett CM, Sassi-Gaha S, Hope JL, Feghali-Bostwick CA, Katsikis PD.

Arthritis Res Ther. 2017 Jun 17;19(1):144. doi: 10.1186/s13075-017-1331-z.

10.

The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis.

Kurowska-Stolarska M, Hasoo MK, Welsh DJ, Stewart L, McIntyre D, Morton BE, Johnstone S, Miller AM, Asquith DL, Millar NL, Millar AB, Feghali-Bostwick CA, Hirani N, Crick PJ, Wang Y, Griffiths WJ, McInnes IB, McSharry C.

J Allergy Clin Immunol. 2017 Jun;139(6):1946-1956. doi: 10.1016/j.jaci.2016.09.021. Epub 2016 Oct 14.

11.

Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes.

Peoples C, Medsger TA Jr, Lucas M, Rosario BL, Feghali-Bostwick CA.

J Scleroderma Relat Disord. 2016 May-Aug;1(2):177-240. doi: 10.5301/jsrd.5000209. Epub 2016 Jul 23.

12.

Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.

Sun H, Zhu Y, Pan H, Chen X, Balestrini JL, Lam TT, Kanyo JE, Eichmann A, Gulati M, Fares WH, Bai H, Feghali-Bostwick CA, Gan Y, Peng X, Moore MW, White ES, Sava P, Gonzalez AL, Cheng Y, Niklason LE, Herzog EL.

Arthritis Rheumatol. 2016 May;68(5):1251-61. doi: 10.1002/art.39575.

13.

Genetics of systemic sclerosis: recent advances.

Ramos PS, Silver RM, Feghali-Bostwick CA.

Curr Opin Rheumatol. 2015 Nov;27(6):521-9. doi: 10.1097/BOR.0000000000000214. Review.

14.

Lipoxin A4 Attenuates Constitutive and TGF-β1-Dependent Profibrotic Activity in Human Lung Myofibroblasts.

Roach KM, Feghali-Bostwick CA, Amrani Y, Bradding P.

J Immunol. 2015 Sep 15;195(6):2852-60. doi: 10.4049/jimmunol.1500936. Epub 2015 Aug 14.

15.

Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

Torok KS, Kurzinski K, Kelsey C, Yabes J, Magee K, Vallejo AN, Medsger T Jr, Feghali-Bostwick CA.

Semin Arthritis Rheum. 2015 Dec;45(3):284-93. doi: 10.1016/j.semarthrit.2015.06.006. Epub 2015 Jun 17.

16.

Anti-RNA Polymerase II Antibodies in a U.S. Cohort of Systemic Sclerosis Patients: Comment on the Article by Hamaguchi et al.

Patel V, Assassi S, Mayes MD, Feghali-Bostwick CA.

Arthritis Rheumatol. 2015 Sep;67(9):2547-8. doi: 10.1002/art.39203. No abstract available.

17.

Induced pluripotent stem cells model personalized variations in liver disease resulting from α1-antitrypsin deficiency.

Tafaleng EN, Chakraborty S, Han B, Hale P, Wu W, Soto-Gutierrez A, Feghali-Bostwick CA, Wilson AA, Kotton DN, Nagaya M, Strom SC, Roy-Chowdhury J, Stolz DB, Perlmutter DH, Fox IJ.

Hepatology. 2015 Jul;62(1):147-57. doi: 10.1002/hep.27753. Epub 2015 Apr 13.

18.

Update on scleroderma-associated interstitial lung disease.

Fan MH, Feghali-Bostwick CA, Silver RM.

Curr Opin Rheumatol. 2014 Nov;26(6):630-6. doi: 10.1097/BOR.0000000000000111. Review.

19.

Fibroblasts in fibrosis: novel roles and mediators.

Kendall RT, Feghali-Bostwick CA.

Front Pharmacol. 2014 May 27;5:123. doi: 10.3389/fphar.2014.00123. eCollection 2014. Review.

20.

A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.

Coward WR, Feghali-Bostwick CA, Jenkins G, Knox AJ, Pang L.

FASEB J. 2014 Jul;28(7):3183-96. doi: 10.1096/fj.13-241760. Epub 2014 Mar 20.

21.

Editorial: molecular insights into systemic sclerosis-associated interstitial lung disease.

Silver RM, Feghali-Bostwick CA.

Arthritis Rheumatol. 2014 Mar;66(3):485-7. doi: 10.1002/art.38287. No abstract available.

22.

The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis.

Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA.

PLoS One. 2014 Feb 13;9(2):e87754. doi: 10.1371/journal.pone.0087754. eCollection 2014.

23.

Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma.

Magee KE, Kelsey CE, Kurzinski KL, Ho J, Mlakar LR, Feghali-Bostwick CA, Torok KS.

Arthritis Res Ther. 2013;15(6):R188.

24.

Role of endostatin in fibroproliferative disorders.-as a candidate for anti-fibrosis therapy-.

Yamaguchi Y, Feghali-Bostwick CA.

Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(6):452-8. Review.

25.

HIV gp120 induces mucus formation in human bronchial epithelial cells through CXCR4/α7-nicotinic acetylcholine receptors.

Gundavarapu S, Mishra NC, Singh SP, Langley RJ, Saeed AI, Feghali-Bostwick CA, McIntosh JM, Hutt J, Hegde R, Buch S, Sopori ML.

PLoS One. 2013 Oct 14;8(10):e77160. doi: 10.1371/journal.pone.0077160. eCollection 2013.

26.

Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-κB and activator protein-1.

Deng X, Xu M, Yuan C, Yin L, Chen X, Zhou X, Li G, Fu Y, Feghali-Bostwick CA, Pang L.

Int J Biochem Cell Biol. 2013 Jul;45(7):1366-76. doi: 10.1016/j.biocel.2013.04.003. Epub 2013 Apr 10.

PMID:
23583295
27.

Telomerase and telomere length in pulmonary fibrosis.

Liu T, Ullenbruch M, Young Choi Y, Yu H, Ding L, Xaubet A, Pereda J, Feghali-Bostwick CA, Bitterman PB, Henke CA, Pardo A, Selman M, Phan SH.

Am J Respir Cell Mol Biol. 2013 Aug;49(2):260-8. doi: 10.1165/rcmb.2012-0514OC.

28.

Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis.

Aida-Yasuoka K, Peoples C, Yasuoka H, Hershberger P, Thiel K, Cauley JA, Medsger TA Jr, Feghali-Bostwick CA.

Arthritis Res Ther. 2013 Jan 10;15(1):R10. doi: 10.1186/ar4140.

29.

Antifibrotic effects of roscovitine in normal and scleroderma fibroblasts.

Steinman RA, Robinson AR, Feghali-Bostwick CA.

PLoS One. 2012;7(11):e48560. doi: 10.1371/journal.pone.0048560. Epub 2012 Nov 20.

30.

Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis.

Ruiz XD, Mlakar LR, Yamaguchi Y, Su Y, Larregina AT, Pilewski JM, Feghali-Bostwick CA.

PLoS One. 2012;7(8):e43049. doi: 10.1371/journal.pone.0043049. Epub 2012 Aug 10.

31.

X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma.

Selmi C, Feghali-Bostwick CA, Lleo A, Lombardi SA, De Santis M, Cavaciocchi F, Zammataro L, Mitchell MM, Lasalle JM, Medsger T Jr, Gershwin ME.

Clin Exp Immunol. 2012 Sep;169(3):253-62. doi: 10.1111/j.1365-2249.2012.04621.x.

32.

Insulin-like growth factor binding proteins-3 and -5: central mediators of fibrosis and promising new therapeutic targets.

Veraldi KL, Feghali-Bostwick CA.

Open Rheumatol J. 2012;6:140-5. doi: 10.2174/1874312901206010140. Epub 2012 Jun 15.

33.

A peptide derived from endostatin ameliorates organ fibrosis.

Yamaguchi Y, Takihara T, Chambers RA, Veraldi KL, Larregina AT, Feghali-Bostwick CA.

Sci Transl Med. 2012 May 30;4(136):136ra71. doi: 10.1126/scitranslmed.3003421.

34.

Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3.

Brissett M, Veraldi KL, Pilewski JM, Medsger TA Jr, Feghali-Bostwick CA.

Arthritis Rheum. 2012 Jan;64(1):272-80. doi: 10.1002/art.30647.

35.

The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.

Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA, Katsikis PD.

Arthritis Rheum. 2011 Nov;63(11):3563-74. doi: 10.1002/art.30568.

36.

The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses.

Fang F, Ooka K, Bhattacharyya S, Wei J, Wu M, Du P, Lin S, Del Galdo F, Feghali-Bostwick CA, Varga J.

Am J Pathol. 2011 May;178(5):2077-90. doi: 10.1016/j.ajpath.2011.01.035. Erratum in: Am J Pathol. 2011 Jul;179(1):537. Bhattachyya, Swati [corrected to Bhattacharyya, Swati].

37.

Autoimmunity in idiopathic pulmonary fibrosis: are circulating autoantibodies pathogenic or epiphenomena?

Feghali-Bostwick CA, Wilkes DS.

Am J Respir Crit Care Med. 2011 Mar 15;183(6):692-3. doi: 10.1164/rccm.201010-1727ED. No abstract available.

PMID:
21471064
38.

Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation.

Lam AP, Flozak AS, Russell S, Wei J, Jain M, Mutlu GM, Budinger GR, Feghali-Bostwick CA, Varga J, Gottardi CJ.

Am J Respir Cell Mol Biol. 2011 Nov;45(5):915-22. doi: 10.1165/rcmb.2010-0113OC. Epub 2011 Mar 31.

39.

The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis.

Xue J, Gochuico BR, Alawad AS, Feghali-Bostwick CA, Noth I, Nathan SD, Rosen GD, Rosas IO, Dacic S, Ocak I, Fuhrman CR, Cuenco KT, Smith MA, Jacobs SS, Zeevi A, Morel PA, Pilewski JM, Valentine VG, Gibson KF, Kaminski N, Sciurba FC, Zhang Y, Duncan SR.

PLoS One. 2011 Feb 23;6(2):e14715. doi: 10.1371/journal.pone.0014715.

40.

Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension.

Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA.

Arthritis Rheum. 2011 Mar;63(3):783-94. doi: 10.1002/art.30159.

41.

Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease.

Veraldi KL, Hsu E, Feghali-Bostwick CA.

Curr Rheumatol Rep. 2010 Feb;12(1):19-25. doi: 10.1007/s11926-009-0071-8. Review.

PMID:
20425529
42.

Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis.

Coward WR, Watts K, Feghali-Bostwick CA, Jenkins G, Pang L.

Mol Cell Biol. 2010 Jun;30(12):2874-86. doi: 10.1128/MCB.01527-09. Epub 2010 Apr 19.

43.

Decreased caveolin-1 levels contribute to fibrosis and deposition of extracellular IGFBP-5.

Yamaguchi Y, Yasuoka H, Stolz DB, Feghali-Bostwick CA.

J Cell Mol Med. 2011 Apr;15(4):957-69. doi: 10.1111/j.1582-4934.2010.01063.x.

44.

The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms.

Yasuoka H, Hsu E, Ruiz XD, Steinman RA, Choi AM, Feghali-Bostwick CA.

Am J Pathol. 2009 Aug;175(2):605-15. doi: 10.2353/ajpath.2009.080991. Epub 2009 Jul 23.

45.

Role of insulin-like growth factor binding protein-3 in allergic airway remodeling.

Veraldi KL, Gibson BT, Yasuoka H, Myerburg MM, Kelly EA, Balzar S, Jarjour NN, Pilewski JM, Wenzel SE, Feghali-Bostwick CA.

Am J Respir Crit Care Med. 2009 Oct 1;180(7):611-7. doi: 10.1164/rccm.200810-1555OC. Epub 2009 Jul 16.

46.

Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis.

Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr, Feghali-Bostwick CA.

Arthritis Rheum. 2009 Jul 15;61(7):958-65. doi: 10.1002/art.24586.

47.

Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis.

Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L.

Mol Cell Biol. 2009 Aug;29(15):4325-39. doi: 10.1128/MCB.01776-08. Epub 2009 Jun 1.

48.

The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration.

Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA.

Am J Respir Cell Mol Biol. 2009 Aug;41(2):179-88. doi: 10.1165/rcmb.2008-0211OC. Epub 2009 Jan 8.

49.

Human skin culture as an ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins.

Yasuoka H, Larregina AT, Yamaguchi Y, Feghali-Bostwick CA.

Open Rheumatol J. 2008;2:17-22. doi: 10.2174/1874312900802010017. Epub 2008 Mar 28.

Supplemental Content

Loading ...
Support Center